randi isaacs (Novartis)
90
Structured Review
Novartis
randi isaacs
Randi Isaacs, supplied by Novartis, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/randi+isaacs/randi+isaacs/pmc06075847-16-341-343
Average 90 stars, based on 1 article reviews
Randi Isaacs, supplied by Novartis, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/randi+isaacs/randi+isaacs/pmc06075847-16-341-343
Average 90 stars, based on 1 article reviews
randi isaacs - by Bioz Stars,
2026-10
90/100 stars
Images
Related Articles
other:Article Title: Phase II Study of BGJ398 in Patients With FGFR-Altered Advanced Cholangiocarcinoma Article Snippet: Published online 2017 Nov 28. doi: [ 10.1200/JCO.2017.75.5009 ] PMCID: PMC6075847 PMID: 29182496 Milind Javle , Maeve Lowery , Rachna T. Shroff , Karl Heinz Weiss , Christoph Springfeld , Mitesh J. Borad , Ramesh K. Ramanathan , Lipika Goyal , Saeed Sadeghi , Teresa Macarulla , Anthony El-Khoueiry , Robin Kate Kelley , Ivan Borbath , Su Pin Choo , Do-Youn Oh , Philip A. Philip , Li-Tzong Chen , Thanyanan Reungwetwattana , Eric Van Cutsem , Kun-Huei Yeh , Kristen Ciombor , Richard S. Finn , Anuradha Patel , Suman Sen , Dale Porter , Randi Isaacs , Andrew X. Zhu , Ghassan K. Abou-Alfa , and Tanios Bekaii-Saab Milind Javle Milind Javle and Rachna T. Shroff, The University of Texas MD Anderson Cancer Center, Houston, TX; Maeve Lowery and Ghassan K. Abou-Alfa, Memorial Sloan Kettering Cancer Center, and Weill Cornell Medical College, New York, NY; Karl Heinz Weiss and Christoph Springfeld, Universitäts Klinikum Heidelberg, Heidelberg, Germany; Mitesh J. Borad, Ramesh K. Ramanathan, and Tanios Bekaii-Saab, Mayo Clinic, Phoenix, AZ; Lipika Goyal and Andrew X. Zhu, Massachusetts General Hospital Cancer Center, Boston, MA; Saeed Sadeghi and Richard S. Finn, David Geffen School of Medicine at UCLA; Anthony El-Khoueiry, USC Norris Comprehensive Cancer Center, Keck School of Medicine, Los Angeles; Robin Kate Kelley, UCSF Helen Diller Family Comprehensive Cancer Center, San Francisco, CA; Teresa Macarulla, Vall d’Hebron University Hospital and Vall d’Hebron Institute of Oncology, Barcelona, Spain; Ivan Borbath, Cliniques Universitaires Saint-Luc, Brussels; Eric Van Cutsem, University Hospitals Gasthuisberg and KU Leuven, Leuven, Belgium; Su Pin Choo, National Cancer Centre of Singapore, Singapore; Do-Youn Oh, Seoul National University, Seoul, South Korea; Philip A. Philip, Karmanos Cancer Institute, Detroit, MI; Li-Tzong Chen, National Institute of Cancer Research and National Cheng Kung University Hospital, Tainan; Kun-Huei Yeh, National Taiwan University Hospital Cancer Center, and Cancer Research Center, National Taiwan University College of Medicine, Taipei, Taiwan; Article Title: Phase II Study of BGJ398 in Patients With FGFR-Altered Advanced Cholangiocarcinoma Article Snippet: Find articles by Dale Porter Randi Isaacs Milind Javle and Rachna T. Shroff, The University of Texas MD Anderson Cancer Center, Houston, TX; Maeve Lowery and Ghassan K. Abou-Alfa, Memorial Sloan Kettering Cancer Center, and Weill Cornell Medical College, New York, NY; Karl Heinz Weiss and Christoph Springfeld, Universitäts Klinikum Heidelberg, Heidelberg, Germany; Mitesh J. Borad, Ramesh K. Ramanathan, and Tanios Bekaii-Saab, Mayo Clinic, Phoenix, AZ; Lipika Goyal and Andrew X. Zhu, Massachusetts General Hospital Cancer Center, Boston, MA; Saeed Sadeghi and Richard S. Finn, David Geffen School of Medicine at UCLA; Anthony El-Khoueiry, USC Norris Comprehensive Cancer Center, Keck School of Medicine, Los Angeles; Robin Kate Kelley, UCSF Helen Diller Family Comprehensive Cancer Center, San Francisco, CA; Teresa Macarulla, Vall d’Hebron University Hospital and Vall d’Hebron Institute of Oncology, Barcelona, Spain; Ivan Borbath, Cliniques Universitaires Saint-Luc, Brussels; Eric Van Cutsem, University Hospitals Gasthuisberg and KU Leuven, Leuven, Belgium; Su Pin Choo, National Cancer Centre of Singapore, Singapore; Do-Youn Oh, Seoul National University, Seoul, South Korea; Philip A. Philip, Karmanos Cancer Institute, Detroit, MI; Li-Tzong Chen, National Institute of Cancer Research and National Cheng Kung University Hospital, Tainan; Kun-Huei Yeh, National Taiwan University Hospital Cancer Center, and Cancer Research Center, National Taiwan University College of Medicine, Taipei, Taiwan; |